U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Surveillance: Post Drug-Approval Activities
  5. FDA's Adverse Event Reporting System (FAERS)
  6. FDA Adverse Event Reporting System (FAERS) Electronic Submissions – E2B(R2) Standards
  1. FDA's Adverse Event Reporting System (FAERS)

FDA Adverse Event Reporting System (FAERS) Electronic Submissions – E2B(R2) Standards

This page provides industry information and instructions on how to electronically submit postmarketing individual case safety reports (ICSRs) for human drugs, including biological products regulated by CDER, using E2B(R2) standards. Companies submitting postmarketing ICSRs to FAERS may continue using E2B(R2) standards for  (2) years during the E2B(R3) implementation period. Once your company has begun submitting in the E2B(R3) standard, your company may not revert to legacy methods and/or standards.

FDA has only accepted electronic submissions of ISCRs in the XML format if prepared in accordance with International Conference on Harmonisation-E2B (ICH E2B) to transmit information directly from database-to-database using standardized (ICH E2B(M)) data elements.

To submit ICSRs using database-to-database transmission in E2B(R2) format:

Back to Top